Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06256003 · ClinicalTrials.gov registry record · NA

Assessing Mobile Apps for Adult ADHD

A NA study, sponsored by Think Now Incorporated.

Completed
Registry status
NA
Development phase
140
Enrollment target

NCT06256003: Completed NA study, sponsored by Think Now Incorporated.

NCT06256003 is a NA study that has completed, run by Think Now Incorporated. The registered enrollment target is 140 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06256003, a NA study, has completed, sponsored by Think Now Incorporated.

COMPLETED
Registry status
NA
Development phase
140 participants
Enrollment target

Study Summary

The purpose of this clinical trial is to evaluate the effects of mobile app digital therapies on cognitive function and symptoms in adults diagnosed with ADHD.

Primary Outcome

Conners CPT-HRT Std (Hit Reaction Time Standard Deviation) is the standard deviation of the reaction time of hits to target stimuli over the entire test. The calculation of the difference between Baseline and Midpoint (Mid-treatment) in the Conners HRT Std is HRT Std at Day 25 minus HRT Std at Day 0; and the difference between Baseline and Endpoint (Post-treatment) is HRT Std at Day 50 minus HRT Std at Day 0. Higher scores represent more variability in responding, reflecting poorer sustained att

Interventions

  • DEVICE UC-A
  • DEVICE UC-N

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2024-01-03
Est. Completion 2024-11-23
Phase NA
Think Now Incorporated

4 total trials

What the finished NCT06256003 record still lists

NCT06256003 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 2 interventions - of which UC-A is the first listed.

NCT06256003 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06256003 about?

NCT06256003 is a clinical study titled "Assessing Mobile Apps for Adult ADHD". The purpose of this clinical trial is to evaluate the effects of mobile app digital therapies on cognitive function and symptoms in adults diagnosed with ADHD.

What is the current status of trial NCT06256003?

This trial is currently completed. It is a NA study. The enrollment target is 140 participants. The study started on 2024-01-03. Estimated completion is 2024-11-23.

What interventions are being tested in trial NCT06256003?

The interventions under investigation include: UC-A (DEVICE), UC-N (DEVICE).

Who is sponsoring clinical trial NCT06256003?

This trial is sponsored by Think Now Incorporated, which has 4 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06256003's enrollment target sits among peer trials

140 713th of 2000 higher than 1,281 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01419561 · 140 participants · Phase 2

    Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

  • NCT01624805 · 140 participants · Phase 2

    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

  • NCT02369770 · 140 participants · NA

    Sensory-Motor Rehabilitation Post Stroke

  • NCT02455193 · 140 participants · NA

    Neuronal Effects of Exercise in Schizophrenia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06256003, the US trial registry maintained by the National Library of Medicine. NCT06256003 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.